

INTERNATIONAL COOPERATION TREATY

M

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:
MICHAEL S. TUCAN
MORGAN, LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE, NW
WASHINGTON, DC 20004

Date of Mailing
(day/month/year) **02 JUL 2003**

Applicant's or agent's file reference
44921-5038W1

FOR FURTHER ACTION See paragraphs 1 and 4 below

International application No.
PCT/US03/03194

International filing date
(day/month/year)
31 January 2003 (31.01.2003)

Applicant
GENE LOGIC INC

1. The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.

Where? Directly to the International Bureau of WIPO, 34, chemin des Colombettes
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. **With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:**
 the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. **Reminders**

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90 *bis*.1 and 90 *bis*.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase **until 30 months** from the priority date (in some Offices even later); otherwise the applicant must, **within 20 months** from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of **30 months** (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time-limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230

Authorized officer
Cheyne Ly
Telephone No. 703 308-0196

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under Article 19. The Notes are based on the requirements of the Patent Cooperation Treaty and of the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule" and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended ?

The claims only.

The description and the drawings may only be amended during international preliminary examination under Chapter II.

When ? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments ?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How ? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

What documents must/may accompany the amendments ?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confounded with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 44921-5038W1	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US03/03194	International filing date (<i>day/month/year</i>) 31 January 2003 (31.01.2003)	(Earliest) Priority Date (<i>day/month/year</i>) 31 January 2002 (31.01.2002)
Applicant GENE LOGIC, INC.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the Report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. Certain claims were found unsearchable (See Box I).

3. **Unity of invention is lacking** (See Box II).

4. With regard to the **title**,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No. _____

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

None of the figures

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/03194

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7, 12-20 and 53-56; carcinogenesis and acetaminophen
- Remark on Protest The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/03194

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : G01N 33/48; G06F 19/00
 US CL : 702/19, 27
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 702/19, 27

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6,218,122 B1 (FRIEND et al.) 17 April 2001 (17.04.2001), see column 1, lines 50-61; column 7, lines 5-15, column 9, lines 15-19; column 10, lines 40-46 and lines 57-64;	1-6, 12-19 and 53-56
---		-----
Y	column 11, lines 35-45; column 13, lines 49-56; column 21, lines 52-56 and column 23, lines 19-26.	7 and 20
Y	US 2001/0049139 A1 (LAGASSE et al.) 06 December 2001 (06.12.2001), see paragraphs 0032 and 0042.	7 and 20

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 24 June 2003 (24.06.2003)	Date of mailing of the international search report 02 JUL 2003
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Authorized officer <i>Chayne D Ey</i> Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US03/03194

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-7, 12-20, and 53-56, drawn to a method of predicting at least one toxic effect of a compound.

Group II, claim(s) 8, 12-17, 20, and 53-56, drawn to a method of predicting the progression of a toxic effect of a compound.

Group III, claim(s) 9, 12-17, 21, and 53-56, drawn to a method of predicting the hepatotoxicity of a compound.

Group IV, claim(s) 10, 12-17, and 53-56, drawn to a method of identifying an agent that modulates the onset or progression of a toxic response.

Group V claim(s) 11, 12-17, 22, and 53-56, drawn to a method of predicting the cellular pathways that a compound modulates in a cell.

Group VI, claim(s) 23-29, drawn to a set of at least two probes.

Group VII, claim(s) 30-34 and 50-52, drawn to a solid support comprising at least two probes.

Group VIII, claim(s) 35-49 and 64, drawn to a computer system with a database containing information identifying the expression level in a tissue or cell.

Group IX, claim(s) 57-63, drawn to a method of identifying an agent that modulates at least one activity of a protein encoded by a gene.

Group X, claim(s) 65, drawn to an array comprising probes which individually specifically hybridize to all of the genes in specified tables.

.2, they lack the same or corresponding special technical features for the following reasons:

Group I is directed to a method of predicting at least one toxic effect of a compound.

Group II is directed to a method of predicting the progression of a toxic effect of a compound.

Group III is directed to a method of predicting the hepatotoxicity of a compound.

Group IV is directed to a method of identifying an agent that modulates the onset or progression of a toxic response.

Group V is directed to a method of predicting the cellular pathways that a compound modulates in a cell.

Group VI is directed to a set of at least two probes.

Group VII is directed to a solid support comprising at least two probes.

Group VIII is directed to a computer system with a database containing information identifying the expression level in a tissue or cell.

Group IX is directed to a method of identifying an agent that modulates at least one activity of a protein encoded by a gene.

Group X is directed to an array comprising probes which individually specifically hybridize to all of the genes in specified tables.

INTERNATIONAL SEARCH REPORT

PCT/US03/03194

Clearly, these 10 Groups lack the same or corresponding special technical features. Thus, Groups I-X are directed to different special technical features and thus support this lack of unity.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

Specific to Groups I-V, VIII, and IX, the claims of these groups include a series of generic technical features directed to diseases (claim 20) and toxins (claim 22). The technical group containing diseases have 8 species. The technical group containing toxins have 30 species. These species within each technical feature is distinct characterized by its functional properties, thus, each is its own special technical feature.

The first Group has been identified as Group I having species of carcinogenesis and acetaminophen.

Election of a species of the disease and toxin is required for Groups I-V, VIII and IX. For each additional species for each Group, the fee for each additional Group is \$210.00 and each additional specie is \$210.

Specific to Groups VI, VII, and X, these inventions are directed to at least two sequences (4295 SEQ ID NOs) listed in specified tables and each SEQ ID Nos: has its own special technical features. Therefore, if Group VI, VII, or X is the elected Group, an additional fee of \$210.00 is required for each Group and \$210 for each pair of SEQ ID Nos: from 1-4295 (2148 pairs).

The total for search reports on the inventions of Group I-X and all the species is \$1,705,830.